Survey Finds Majority Of Affected Americans Approve Of Psychedelics As An Alternative Treatment To Address Anxiety, Depression & PTSD

A new survey conducted by The Harris Poll on behalf of Delic Holdings Corp (Delic), a leader in new medicines and treatments for a modern world, reports that nearly two thirds of Americans with anxiety/depression/post-traumatic stress disorder (PTSD) (65%) believe that psychedelic medicine (i.e. ketamine, psilocybin and MDMA) should be made available to consumers with treatment-resistant anxiety, depression or PTSD.

According to the survey, conducted online in December 2021 among 953 U.S. adults with anxiety/depression/PTSD, nearly two-thirds (63%) of Americans who have used prescription medications to treat anxiety/depression/PTSD say . . .